Inhibitory effects of N-methyl-D-aspartate (NMDA) and α
IKur
Ifenprodil
Ultra-rapid delayed rectifier K+ current
hKv1.5
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
12
12
2022
accepted:
04
05
2023
pubmed:
11
5
2023
medline:
11
5
2023
entrez:
11
5
2023
Statut:
ppublish
Résumé
Ifenprodil has been known to reduce cardiac contractility and cerebral vasodilation by antagonizing α
Identifiants
pubmed: 37166464
doi: 10.1007/s00210-023-02521-6
pii: 10.1007/s00210-023-02521-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3149-3161Subventions
Organisme : Ministry of Science and ICT, South Korea
ID : 2020R1A2C1013958
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Aydar E, Palmer CP, Klyachko VA, Jackson MB (2002) The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34(3):399–410
pubmed: 11988171
doi: 10.1016/S0896-6273(02)00677-3
Bath CP, Farrell LN, Gilmore J, Ward MA, Hicks CA, O’Neill MJ, Bleakman D (1996) The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia. Eur J Pharmacol 299(1–3):103–112
pubmed: 8901012
doi: 10.1016/0014-2999(95)00846-2
Bettahi I, Marker CL, Roman MI, Wickman K (2002) Contribution of the Kir3.1 subunit to the muscarinic-gated atrial potassium channel IKACh. J Biol Chem 277:48282–48288
pubmed: 12374786
doi: 10.1074/jbc.M209599200
Brittain MK, Brustovetsky T, Brittain JM, Khanna R, Cummins TR, Brustovetsky N (2012) Ifenprodil, a NR2B-selective antagonist of NMDA receptor, inhibits reverse Na+/Ca2+ exchanger in neurons. Neuropharmacology 63(6):974–982
pubmed: 22820271
pmcid: 3427421
doi: 10.1016/j.neuropharm.2012.07.012
Brunner M, Kodirov S, Mitchell GF, Buckett PD, Shibata K, Folco EJ, Baker L, Salama G, Chan DP, Zhou J, Koren G (2003) In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol Heart Circ Physiol 285:H194–H203
pubmed: 12793978
doi: 10.1152/ajpheart.00971.2002
Carron C, Jullien A, Bucher B (1971) Synthesis and pharmacological properties of a series of 2-piperidino alkanol derivatives. Arzneimittelforschung 21:1992–1998
Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, Fox CB (1991) Separation of alpha 1adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34:3085–3090
pubmed: 1681106
doi: 10.1021/jm00114a018
Choi BH, Choi JS, Jeong SW, Hahn SJ, Yoon SH, Jo YH, Kim MS (2000) Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 293:634–640
pubmed: 10773038
Christ T, Wettwer E, Voigt N, Hála O, Radicke S, Matschke K, Várro A, Dobrev D, Ravens U (2008) Pathology-specific effects of the IKur/Ito/IK, ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol 154:1619–1630
pubmed: 18536759
pmcid: 2518460
doi: 10.1038/bjp.2008.209
Christophersen IE, Olesen MS, Liang B, Andersen MN, Larsen AP, Nielsen JB, Haunsø S, Olesen SP, Tveit A, Svendsen JH, Schmitt N (2013) Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur Heart J 34:1517–1525
pubmed: 23264583
doi: 10.1093/eurheartj/ehs442
Church J, Fletcher EJ, Baxter K, MacDonald JF (1994) Blockade by ifenprodil of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones: comparison with N-methyl-D-aspartate receptor antagonist actions. Br J Pharmacol 113(2):499–507
pubmed: 7834201
pmcid: 1510127
doi: 10.1111/j.1476-5381.1994.tb17017.x
Colatsky TJ, Follmer CH, Starmer CF (1990) Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 82:2235–2242
pubmed: 2242545
doi: 10.1161/01.CIR.82.6.2235
Delpon E, Valenzuela C, Gay P, Franqueza L, Snyders DJ, Tamargo J (1997) Block of human cardiac Kv1.5 channels by loratadine: voltage-, time-, and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 35:341–350
pubmed: 9349397
doi: 10.1016/S0008-6363(97)00121-1
Doupnik CA, Davidson N, Lester HA (1995) The inward rectifier potassium channel family. Curr Opin Neurobiol 5:268–277
pubmed: 7580148
doi: 10.1016/0959-4388(95)80038-7
Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S (2008) Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 51:787–792
pubmed: 18294561
doi: 10.1016/j.jacc.2007.08.067
Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S, Brown AM (1993) Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res 73:210–216
pubmed: 8508531
doi: 10.1161/01.RES.73.1.210
Ford JW, Milnes JT (2008) New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol 52:105–120
pubmed: 18670369
doi: 10.1097/FJC.0b013e3181719b0c
Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath Z, Matschke K, Varro A, Ravens U (2013) Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol 61:408–415
pubmed: 23364608
doi: 10.1097/FJC.0b013e31828780eb
Ford J, Milnes J, El Haou S, Wettwer E, Loose S, Matschke K, Tyl B, Round P, Ravens U (2016) The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm 13:555–564
pubmed: 26455450
doi: 10.1016/j.hrthm.2015.10.003
Guo X, Chen W, Sun H, You Q (2016) Kv1.5 inhibitors for treatment of atrial fibrillation: a tradeoff between selectivity and non-selectivity. Curr Top Med Chem 16:1843–1854
pubmed: 26975505
doi: 10.2174/1568026616666160315142647
Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stühmer W, Wang X (2005) International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57:473–508
pubmed: 16382104
doi: 10.1124/pr.57.4.10
Hashimoto K, London ED (1993) Further characterization of [3H] ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 236:159–163
pubmed: 8319742
doi: 10.1016/0014-2999(93)90241-9
Hashimoto K, London ED (1995) Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 273:307–310
pubmed: 7737340
doi: 10.1016/0014-2999(94)00763-W
Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED (1994) Further characterization of [3H] ifenprodil binding in rat brain. Eur J Pharmacol 266:67–77
pubmed: 7907988
doi: 10.1016/0922-4106(94)90211-9
Hautz T, Krapf C, Grahammer J, Zelger B, Hickethier T, Seger C, Eberhart N, Wallner C, Messner F, Kotsch K, Griesmacher A, Brandacher G, Lee WP, Margreiter R, Pratschke J, Glossmann H, Schneeberger S (2013) Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation: a pilot study. Transpl Int 26:552–561
pubmed: 23489391
doi: 10.1111/tri.12080
Hayashi K, Konno T, Tada H, Tani S, Liu L, Fujino N, Nohara A, Hodatsu A, Tsuda T, Tanaka Y, Kawashiri MA, Ino H, Makita N, Yamagishi M (2015) Functional characterization of rare variants implicated in susceptibility to lone atrial fibrillation. Circ Arrhythm Electrophysiol 8:1095–1104
pubmed: 26129877
doi: 10.1161/CIRCEP.114.002519
Hu L, Wang T, Gocke AR, Nath A, Zhang H, Margolick JB, Whartenby KA, Calabresi PA (2013) Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes. PLoS ONE 8:e54267
Hwang S, Kim JH, Jo SH (2021) Inhibitory effect of the selective serotonin reuptake inhibitor paroxetine on human Kv1.3 channels. Eur J Pharmacol 912:174567
Jo SH, Hong HK, Chong SH, Choe H (2008) Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel. Life Sci 82:331–340
pubmed: 18191158
doi: 10.1016/j.lfs.2007.12.004
Karbon EW, Patch RJ, Pontecorvo MJ, Ferkany JW (1990) Ifenprodil potently interacts with [3H](+)-3-PPP-labeled sigma binding sites in guinea pig brain membranes. Eur J Pharmacol 176:247–248
pubmed: 2155803
doi: 10.1016/0014-2999(90)90538-H
Kidd MW, Bulley S, Jaggar JH (2017) Angiotensin II reduces the surface abundance of KV 1.5 channels in arterial myocytes to stimulate vasoconstriction. J Physiol 595:1607–1618
pubmed: 27958660
pmcid: 5330887
doi: 10.1113/JP272893
Kobayashi T, Washiyama K, Ikeda K (2006) Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology 31:516–524
pubmed: 16123769
doi: 10.1038/sj.npp.1300844
Kotecha SA, Schlichter LC (1999) A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci 19:10680–10693
pubmed: 10594052
pmcid: 6784954
doi: 10.1523/JNEUROSCI.19-24-10680.1999
Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, Clapham DE (1995) The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K+ -channel proteins. Nature 374:135–141
pubmed: 7877685
doi: 10.1038/374135a0
Lee HM, Hahn SJ, Choi BH (2010) Open channel block of Kv1.5 currents by citalopram. Acta Pharmacol Sin 31:429–435
pubmed: 20228830
pmcid: 4007671
doi: 10.1038/aps.2010.14
Lip GY, Tse HF (2007) Management of atrial fibrillation. Lancet 370:604–618
pubmed: 17707756
doi: 10.1016/S0140-6736(07)61300-2
Loose S, Mueller J, Wettwer E, Knaut M, Ford J, Milnes J, Ravens U (2014) Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation. Front Pharmacol 5:26
pubmed: 24624083
pmcid: 3940943
doi: 10.3389/fphar.2014.00026
Marquis P, Lecasble M, Passa P (1998) Quality of life of patient with peripheral arterial obliterative disease treated with ifenprodil tartrate. Results of an ARTEMIS study. Drugs 56(Suppl 3):37–48
McCool BA, Lovinger DM (1995) Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. Neuropharmacology 34:621–629
pubmed: 7566498
doi: 10.1016/0028-3908(95)00030-A
Monassier L, Bousquet P (2002) Sigma receptors: from discovery to highlights of their implications in the cardiovascular system. Fundam Clin Pharmacol 16:1–8
pubmed: 11903506
doi: 10.1046/j.1472-8206.2002.00063.x
Monassier L, Tibiriça E, Roegel JC, Mettauer B, Feldman J, Bousquet P (1994) Prevention by NMDA receptor antagonists of the centrally-evoked increases of cardiac inotropic responses in rabbits. Br J Pharmacol 111:1347–1354
pubmed: 7913376
pmcid: 1910173
doi: 10.1111/j.1476-5381.1994.tb14893.x
Monassier L, Riehl V, Lienhard JP, Tibiriça E, Feldman J, Bousquet P (1999) Effects of ifenprodil and baclofen on exercise-induced increase of myocardial oxygen demand in normotensive rats. J Pharmacol Exp Ther 290(3):1188–1194
pubmed: 10454494
Monassier L, Brandt CM, Bousquet P (2001) Effects of centrally-acting glutamatergic modulators on cardiovascular responses to stress in humans. J Cardiol 37(Suppl 1):77–84
pubmed: 11433832
Monassier L, Manoury B, Bellocq C, Weissenburger J, Greney H, Zimmermann D, Ehrhardt JD, Jaillon P, Baró I, Bousquet P (2007) σ2-Receptor ligand-mediated inhibition of inwardly rectifying K+ channels in the heart. J Pharmacol Exp Ther 322:341–350
pubmed: 17460149
doi: 10.1124/jpet.107.122044
Nakagawa H, Yamano S, Nikawa K, Matsumoto Y, Suga T (1975) Metabolic fate of dl-erythro-2-(4-benzylpiperidino)-1-(4-hydrophenyl)-1-propanol I. Absorption, distribution and excretion in the rat and mouse. Pharmacometrics 10:283–291
Novakova M, Ela C, Bowen WD, Hasin Y, Bowen EYWD, Hasin Y, Eilam Y (1998) Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur J Pharmacol 353:315–327
pubmed: 9726662
doi: 10.1016/S0014-2999(98)00398-7
Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Kmetz J, Bratz I, Luli J, Nagane M, Khan N, Hou H, Kuppusamy P, Graham J, Fu FK et al (2015) Requisite role of Kv1.5 channels in coronary metabolic dilation. Circ Res 117:612–621
pubmed: 26224794
pmcid: 4843795
doi: 10.1161/CIRCRESAHA.115.306642
Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A (2006) Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 15:2185–2191
pubmed: 16772329
doi: 10.1093/hmg/ddl143
Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM, Pitt B, Schwartz PJ, Veltri EP, Waldo AL (1998) Mortality in the survival with ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 81:869–876
pubmed: 9555777
doi: 10.1016/S0002-9149(98)00006-X
Reimann F, Ashcroft FM (1999) Inwardly rectifying potassium channels. Curr Opin Cell Biol 11:503–508
pubmed: 10449331
doi: 10.1016/S0955-0674(99)80073-8
Ru Q, Tian X, Wu YX, Wu RH, Pi MS, Li CY (2014) Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma. Oncol Rep 31:842–848
pubmed: 24284968
doi: 10.3892/or.2013.2875
Seo MS, Kang M, An JR, Heo R, Jung WK, Choi IW, Han ET, Han JH, Chun W, Park WS (2022) Asenapine, an atypical antipsychotic, blocks voltage-gated potassium channels in rabbit coronary artery smooth muscle cells. Eur J Pharmacol 934:175318
pubmed: 36209925
doi: 10.1016/j.ejphar.2022.175318
Suessbrich H, Schönherr R, Heinemann SH, Attali B, Lang F, Busch AE (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120(5):968–974
pubmed: 9138706
pmcid: 1564549
doi: 10.1038/sj.bjp.0700989
Sung MJ, Ahn HS, Hahn SJ, Choi BH (2008) Open channel block of Kv3.1 currents by fluoxetine. J Pharmacol Sci 106:38–45
pubmed: 18187934
doi: 10.1254/jphs.FP0070759
Swanson R, Marshall J, Smith JS, Williams JB, Boyle MB, Folander K, Luneau CJ, Antanavage J, Oliva C, Buhrow SA, Bennet C, Stein RB, Kaczmarek LK (1990) Cloning and expression of cDNA and genomic clones encoding three delayed rectifier potassium channels in rat brain. Neuron 4:929–939
pubmed: 2361015
doi: 10.1016/0896-6273(90)90146-7
Walfridsson H, Anfinsen OG, Berggren A, Frison L, Jensen S, Linhardt G, Nordkam AC, Sundqvist M, Carlsson L (2015) Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans. Europace 17:473–482
pubmed: 25082948
doi: 10.1093/europace/euu192
Wang Z, Fermini B, Nattel S (1993) Sustained depolarization induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 73:1061–1076
pubmed: 8222078
doi: 10.1161/01.RES.73.6.1061
Wettwer E, Hála O, Christ T, Heubach JF, Dobrev D, Knaut M, Varró A, Ravens U (2004) Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110:2299–2306
pubmed: 15477405
doi: 10.1161/01.CIR.0000145155.60288.71
Williams K (2001) Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets 2:285–298
pubmed: 11554553
doi: 10.2174/1389450013348489
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG (2003) The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 111:1703–1713
pubmed: 12782673
pmcid: 156104
doi: 10.1172/JCI16921
Wulff H, Castle NA, Pardo LA (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8:982–1001
pubmed: 19949402
pmcid: 2790170
doi: 10.1038/nrd2983
Yang J, Lu C, Song W, Li J, Ding Y, Zhu Y, Cao J, Ding L, Jia Y, Wen A (2013) Determination of ifenprodil by LC-MS/MS and its application to a pharmacokinetic study in health Chinese volunteers. Act Pharmacuetica Sin B3:180–184
doi: 10.1016/j.apsb.2013.04.001
Young AR, Bouloy M, Boussard JF, Edvinsson L, MacKenzie ET (1981) Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels. J Cereb Blood Flow Metab 1:117–128
pubmed: 7328134
doi: 10.1038/jcbfm.1981.12
Young AR, Barry DI, MacKenzie ET, Robert JP (1983) Cerebro-circulatory effects of socalled “vasodilators” in the anaesthetised rat. Eur Neurol 22:142–153
pubmed: 6840147
doi: 10.1159/000115551